WO2013133677A1 - Composition contenant un mélange réactionnel d'extrait de ginseng rouge et de vinaigre de kaki pour prévenir ou traiter les maladies vasculaires - Google Patents

Composition contenant un mélange réactionnel d'extrait de ginseng rouge et de vinaigre de kaki pour prévenir ou traiter les maladies vasculaires Download PDF

Info

Publication number
WO2013133677A1
WO2013133677A1 PCT/KR2013/001921 KR2013001921W WO2013133677A1 WO 2013133677 A1 WO2013133677 A1 WO 2013133677A1 KR 2013001921 W KR2013001921 W KR 2013001921W WO 2013133677 A1 WO2013133677 A1 WO 2013133677A1
Authority
WO
WIPO (PCT)
Prior art keywords
red ginseng
ginseng extract
comparative example
persimmon vinegar
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2013/001921
Other languages
English (en)
Korean (ko)
Inventor
박종대
이경희
정대영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHEONJIYANG Co Ltd
Original Assignee
CHEONJIYANG Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHEONJIYANG Co Ltd filed Critical CHEONJIYANG Co Ltd
Publication of WO2013133677A1 publication Critical patent/WO2013133677A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/44—Ebenaceae (Ebony family), e.g. persimmon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a composition for the prophylaxis or treatment of vascular diseases containing the persimmon vinegar reaction mixture of ginsenoside Rg 3 and arginine derivative-enhanced red ginseng extract.
  • vascular disease is a serious social problem.
  • the vascular diseases include atherosclerosis, hypertension, angina pectoris, myocardial infarction, ischemic heart disease, heart failure, complications that occur after carotid angioplasty, cerebral infarction, cerebral hemorrhage, and stroke.
  • vascular diseases including hypertension, ischemic heart disease and cerebrovascular disease are the second leading causes of death in Korea, ranking second only to malignant tumors, and men are 55 years old.
  • the mortality rate of vascular disease increases significantly.
  • risk factors associated with atherosclerosis are age, sex, hypertension, hyperlipidemia, diabetes, smoking, lack of exercise and obesity.
  • Patients with vascular disease receive constant medications to treat them, but they are not easy to cure in modern medicine. In addition, the longer the drug is administered, the greater the side effects.
  • hypertension is an increase in arterial blood pressure due to an increase in cardiac output or constriction of peripheral blood vessels.
  • the low incidence of a single disease is caused by stroke, myocardial infarction, diabetes, and heart failure. It is enlarged and is also associated with the development of atherosclerosis.
  • the pressure of blood flow through the blood vessels, ie arterial pressure, is called blood pressure.
  • systolic blood pressure is greater than 120 mmHg (maximum blood pressure) and diastolic blood pressure is greater than 80 mmHg (lowest blood pressure).
  • Hypertension is divided into essential hypertension and secondary hypertension, which accounts for more than 90%. In the case of essential hypertension, there is no specific cure.
  • hypotensive agents such as endothelium dependent relaxing factor (EDRF), or high blood pressure control functions such as catecholamine and the renin-angiotensin system (RAS).
  • EDRF endothelium dependent relaxing factor
  • RAS renin-angiotensin system
  • Angiotensin converting enzyme an important enzyme in the Lenin-Angiotensin system, one of the important mechanisms of blood pressure elevation, is an enzyme that converts angiotensin I and AngII into angiotensin II and AngII. It is known that the converted angiotensin II acts on the angiotensin II-type 1 receptor and constricts blood vessels and increases the release of aldosterone, thereby raising blood pressure (Am. J. Cardiol., 2003, 91 , 30-37). Meanwhile, among the endothelium-derived relaxing factors (EDRFs) in vascular endothelial cells, nitric oxide (NO) is known as the most important factor (Pro. Nat. Acad. Sci.
  • EDRFs endothelium-derived relaxing factors
  • NO nitric oxide
  • NO which is released from vascular endothelial cells, has the effect of inhibiting platelet aggregation and adhesion in addition to vascular smooth muscle relaxation, thereby regulating blood circulation. NO suggests that NO is one of the most active researches in the medical community, suggesting that vascular endothelial cell damage and dysfunction are closely related to ischemic heart disease such as myocardial infarction and angina or adult diseases such as hypertension.
  • angiotensin converting enzyme inhibitors such as enalapril, captopril, ramipril, and lisinopril have been developed and commercialized for the purpose of improving vascular diseases such as hypertension.
  • the use of the drug has been reported side effects such as taste disorders, white blood cell reduction, angioedema, liver failure and dry cough (Elsevier, Amsterdam, 1984, 5, 198-199, 262-263, 298-300).
  • it can be said that it is necessary to search for substances having a therapeutic effect on vascular diseases from natural substances having safety.
  • Red ginseng is a red ginseng made by ginseng roots.
  • Ginseng that can be used to make red ginseng is a perennial plant belonging to the genus Panax. ginseng), hwagisam (Panax quinquefolia), jeonchilsam (thirty-seven, Panax notoginseng), jukjeol three (Panax vietnamensis), Panax elegans tee climb (Panax elegatior), Panax Wan Jia Augustine (Panax wangianus) or Panax non pinra Tippi Douce (Panax bipinratifidus ) and Panax angustifolium .
  • Red ginseng contains a lot of saponins. Most of the saponins in the plant family are oleanane and red ginseng saponins are the dammarane triterpenoid saponins that are rarely found in other plant systems.
  • Red ginseng saponin components include ginsenoside (ginsenoside) Rh 2 , Rg 2 , Rg 3 , Rg 1 , Rh 1 .
  • the general characteristics of saponins are found to be well soluble in water and alcohol, continuously foaming, physiologically detoxifying, and not toxic to overdose.
  • ginsenosides are known to exert a variety of effects on the body regulatory function by affecting the central nervous system, endocrine system, immune system, metabolic system and the like.
  • vascular endothelium is known to promote the release of NO, which is known to relax blood vessels (Gen. Pharmac. 1995, 26 (3), 483-487). It is known that ginsenoside Rg 3 exhibits the strongest activity. The ginsenoside Rg 3 activates K + channels in vascular smooth muscle, thereby inhibiting the influx of intracellular Ca 2+ , thereby vascular relaxation. (Eur. J. Pharmacol. 1999, 367, 41-49).
  • ginsenoside Rg 3 is by increasing the generation of cGMP (cyclic guanosine monophosphate) in the body tissues in addition to facilitating the release of NO relaxation material of endothelial origin indicates a vasodilator acting vasoconstrictive factors on the other hand
  • PGH 2 Prostaglandin H 2
  • antagonistic action is understood to have a protective effect against circulatory disorders ('96 Korea-Japan Ginseng Symposium, 1990, 1 ⁇ 21).
  • ginsenosides Ra 1 , Ra 2 , Ra 3 , Rb 1 , Rb 2 , Rc, and Rd which are protopanaxadiol (PPD) saponins, contain glucose, arabinose, and xyl on carbon 3 and 20. It is a glycoside combined with os, etc. It is a saponin group which accounts for about 70-80% of all saponins of red ginseng. Acid hydrolysis of these saponin groups with acetic acid produces a ginsenoside Rg 3 as the sugar moiety bound to carbon 20 is released, and further, one molecule of glucose bound to carbon 3 of ginsenoside Rg 3 is dropped to ginsenoside. It has been reported that Rh 2 is generated (Korean Journal of Pharmacy, 1991, 35 (5), 432-437; Arch. Pharm. Res., 1995, 18 (3), 164-168; Korean Patent No. 78500)
  • arginine derivatives were generated by a maillard reaction during the heat treatment of red ginseng from fresh ginseng and reportedly produced from arginine and maltose contained in ginseng (Korean J. Ginseng Sci. 1996, 20, 389 ⁇ 415), Arg-Fru-Glc is contained about 5.4% in red ginseng (Hannam University Ph.D. thesis, 2010), Arg-Fru digested by maltase in vivo, -Fru is known to mediate vasodilation by NO ( ⁇ ⁇ . 1995, 233 ⁇ 244).
  • Persimmon is a ripe fruit of the persimmon tree ( Diospyros kaki ), which is used for food in autumn.
  • the taste is characterized by sweet taste, cold nature, and no poison.
  • Penis ( ⁇ ⁇ ) acts on the heart, menopause, large intestine ( ⁇ ⁇ ). Lowers heat and moisturizes the lungs, quenching thirst, eliminating alcoholism and stopping diarrhea.
  • the Chinese herbal medicines are treated with medicinal herbs, roots, roots, leaves, leaves, seeds, and diseases. ), Thalamus, sipi, and sicily.
  • Sicily which is described in the herbaceous wood, is an edifice obtained by processing the immature fruit of persimmon. Take the blue, young and immature fruit, crush it, put it in the dock, pour a small amount of water, stir well, and stir several times. Leave it at room temperature for about 20 days, then squeeze the residue and leave the remaining colorless colloidal solution. This is sicily. Sicily has been reported to be effective in hypertension (Jung-Sup, et al., 2003, 915-918). In Japan, juice has traditionally been known to treat hypertension and suppress heart attacks (Chem. Pharm. Bull., 1990, 38, 1049-1052). Persimmon vinegar can be said to be manufactured similarly to the process of processing such as sicing and juice.
  • Persimmon vinegar is rich in tannins and ascorbic acid (vitamin C), which lowers the acidity of foods, enhances its preservation capacity, stimulates the secretion of digestive fluids through sourness, and stimulates taste buds. It is known to restore fatigue quickly.
  • To make persimmon vinegar simply, put persimmons in a colander or sieve, place a bowl under it, and cover it so that insects do not enter it. When this persimmon is put in a bottle or other container and sealed and aged for about a year, a vinegar with a rich taste is made. The longer the ripening period is, the blacker the taste becomes and the more the organic acid content is.
  • Persimmon vinegar is effective when it is applied to athlete's foot or insect bites, and it has a refreshing taste after drinking greasy or instant foods.It also helps to recover from fatigue, prevent hangovers, relieve stress, sterilize, increase nutrients, and prevent adult diseases. It is known to be effective.
  • the inventors of the present invention while studying a method that can be used as a therapeutic agent for vascular diseases using the red ginseng extract and persimmon vinegar, when the mixture of red ginseng and persimmon vinegar and reacted according to the appropriate temperature and time, ginsenoside Rg 3 And by increasing the content of Arg-Fru, and confirmed that the persimmon vinegar reaction mixture of the red ginseng extract can be used as a therapeutic agent for vascular diseases, the present invention could be completed.
  • Korean Patent No. 759222 discloses a red ginseng vinegar beverage containing licorice, ogapi and rounde extract, red ginseng granules and persimmon vinegar and oligosaccharide, and Korean Patent No. 992800 to acid-treated fermented products of ginseng.
  • Processed ginseng and extracts thereof having increased content of ginsenosides Rg 3 and Rh 2 are disclosed, and the Korean National Patent No. 635025 adds ginseng or ginseng extract to brewing vinegar and heat-extracts at 90-120 ° C. for 6-24 hours.
  • ginseng extracts fortified with ginsenoside Rg 3 have been disclosed, the preceding documents do not disclose that red ginseng or ginseng mixed with persimmon vinegar can be used as a therapeutic agent for vascular diseases. .
  • the antihypertensive effect of ginsenoside Rg 3 is disclosed in Korean Patent No. 504966, a technique different from the composition of the present invention containing arginine derivative and other active ingredients of red ginseng extract in addition to ginsenoside Rg 3 It can be said.
  • An object of the present invention is to provide a composition for the prevention or treatment of vascular diseases containing the persimmon vinegar reaction mixture of ginsenoside Rg 3 and arginine derivatives enhanced red ginseng extract.
  • the present invention relates to a composition for preventing or treating vascular diseases containing red ginseng extract and persimmon vinegar.
  • the vascular disease may be a disease selected from the group consisting of atherosclerosis, hypertension, angina pectoris, myocardial infarction, ischemic heart disease, heart failure, complications occurring after carotid angioplasty, cerebral infarction, cerebral hemorrhage, and stroke.
  • the red ginseng extract may be prepared using any extraction method commonly used, and for example, immersion (cold and warm), hot water extraction, ultrasonic extraction or reflux cooling extraction may be used, but is not limited thereto.
  • the red ginseng extract may be prepared by extracting with an extraction solvent selected from conventional forms of water, aqueous alcohol solution, and alcohol, and these extracts may be prepared alone or by adding an acceptable herbal medicine.
  • the alcohol may be a lower alcohol (C1 to C4 alcohol) having 1 to 4 carbon atoms, and may be preferably selected from ethanol, methanol, propanol, isopropanol and butanol.
  • the red ginseng extract may be a red ginseng extract prepared by removing all the alcohol components from the 70-90% alcohol solution extract of red ginseng and concentrating the solid content to 60% or more.
  • the red ginseng extract is added to the red ginseng, 5-10 times the 70-90% alcohol solution of the weight of red ginseng, and then extracted by heating at 70-90 °C for 4-8 hours, the extract is filtered and filtered After obtaining, it may be a red ginseng extract prepared by removing all the alcohol components in the liquid and concentrated to 60% or more solid content.
  • the red ginseng extract was filtered and then added to the remaining red ginseng 5 to 10 times the 70 ⁇ 90% alcohol solution of the weight of the red ginseng and repeating the heat extraction process for 4 to 8 hours at 70 ⁇ 90 °C 1-5 times
  • the filtrate of the extract extracted repeatedly can be used by concentrating with the first liquid obtained.
  • Persimmon vinegar reaction mixture of the red ginseng extract of the present invention 5 to 20 times (preferably, 8 to 12 times) the persimmon vinegar of the weight of the red ginseng extract to the red ginseng extract and reacted for 1 to 24 hours at 70 ⁇ 90 °C It can manufacture.
  • the reaction temperature is preferably 75 ⁇ 85 °C is the best, the reaction time is the best 12 ⁇ 18 hours.
  • the reactant may be dried to prepare a powder, and for this purpose, a conventional drying method such as reduced pressure drying, spray drying, or freeze drying may be used.
  • the persimmon vinegar used in the present invention can be used commonly used persimmon vinegar, preferably a solid content of 2 to 4%, pH 3.0 to 3.5 can be used persimmon vinegar.
  • composition containing the red ginseng extract and persimmon vinegar of the present invention is preferably,
  • Step 1 adding a red ginseng aqueous solution of 70-90% alcohol of 5-10 times the weight of red ginseng, heat-extracted at 70-90 °C for 4-8 hours to obtain a liquid phase by filtration;
  • the red ginseng extract is filtered in the first step, and the remaining red ginseng is added with an aqueous solution of 70 to 90% alcohol of 5 to 20 times the weight of red ginseng, and then heated and extracted at 70 to 90 ° C. for 4 to 8 hours. After repeated times, the filtered liquid of the extract extracted repeatedly can be used by concentrating with the liquid of the first step obtained first.
  • the concentration method of the two steps can be carried out using a conventional extract concentration process.
  • the pH of persimmon vinegar used in the above three steps is preferably in the range of 3.0 to 3.5, using a solid content of 2 to 4%.
  • ginsenoside Rg 3 and Arg-Fru which is an arginine derivative, may be decomposed and reduced.
  • Drying of the four steps may use a conventional drying method such as reduced pressure drying, spray drying, or freeze drying.
  • composition containing the red ginseng extract and persimmon vinegar of the present invention prepared by the above method may bring an effect of enhancing ginsenoside Rg 3 and Arg-Fru.
  • the extract content of the ginsenoside Rg 3 and the arginine derivative-enhanced red ginseng extract and the active ingredient in the composition for the prevention or treatment of vascular diseases containing a composition containing persimmon vinegar is used in the form and purpose of use, the severity of the patient and the like. It may be appropriately adjusted according to the weight, based on the weight of the solid content may be 0.01 to 99.9% by weight, preferably 0.1 to 50% by weight, but is not limited thereto.
  • compositions may be administered in various oral and parenteral dosage forms during actual clinical administration, and when formulated, diluents or excipients such as fillers, weights, binders, wetting agents, disintegrating agents, and surfactants that are commonly used may be used.
  • diluents or excipients such as fillers, weights, binders, wetting agents, disintegrating agents, and surfactants that are commonly used may be used.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, which solid preparations contain at least one excipient such as starch, cellulose, carbonic acid in a composition containing the persimmon vinegar reaction mixture of red ginseng extract.
  • Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have.
  • Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations.
  • the non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • the dosage of the composition containing the extract of the present invention may vary depending on the patient's worm, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of the disease, depending on the judgment of the doctor or pharmacist
  • the dose may be divided once a day or several times at regular time intervals.
  • the daily dose may be 0.001 to 500 mg / kg, preferably 0.1 to 200 mg / kg, based on the active ingredient content.
  • the present invention provides a health functional food for the prevention or improvement of vascular diseases containing the persimmon vinegar reaction mixture of red ginseng extract.
  • the health functional food may be various foods, beverages, food additives and the like.
  • the content of the extract as an active ingredient contained in the health functional food may be appropriately contained according to the form of the food and the intended use thereof.
  • the extract may be added in an amount of 0.01 to 50% by weight of the total food weight. It can be added at a ratio of 0.1 to 10% by weight.
  • the health beverage composition may be added in a ratio of 0.02 to 10 g, preferably 0.1 to 5 g based on 100 ml.
  • the health beverage composition of the present invention is not particularly limited in the liquid component and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
  • natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose, for example polysaccharides such as maltose and sucrose, and conventional sugars such as dextrin and cyclodextrin. And sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents such as, tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
  • the proportion of natural carbohydrates is generally 1-20 g, preferably 5-12 g per 100 ml of the composition of the present invention.
  • the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.
  • the compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0.001-20 parts by weight per 100 parts by weight of the composition of the present invention.
  • red ginseng or persimmon which is a raw material of the composition of the present invention, has been used in herbal medicine since ancient times. It was found to have no effect in vivo.
  • the composition of the present invention containing red ginseng extract and persimmon vinegar is excellent in increasing NO production and inhibiting angiotensin converting enzyme, such as atherosclerosis, hypertension, angina pectoris, myocardial infarction, ischemic heart disease, heart failure, and carotid angioplasty. It can be usefully used as a composition that can effectively prevent or inhibit vascular diseases, including postoperative complications, cerebral infarction, cerebral hemorrhage, and stroke.
  • Example 1 is a flowchart illustrating a method of preparing a persimmon vinegar reaction mixture of the red ginseng extract disclosed in Example 2 of the present invention.
  • Example 2-18 90 24 Table 1 Condition Temperature (°C) Hour Example 2-1 70 One Example 2-2 70 3 Example 2-3 70 6 Example 2-4 70 12 Example 2-5 70 18 Example 2-6 70 24 Example 2-7 80 One Example 2-8 80 3 Example 2-9 80 6 Example 2-10 80 12 Example 2-11 80 18 Example 2-12 80 24 Example 2-13 90 One Example 2-14 90 3 Example 2-15 90 6 Example 2-16 90 12 Example 2-17 90 18 Example 2-18 90 24
  • the ginseng extract was prepared in the same manner as in Example 1, and instead of the red ginseng extract, a persimmon vinegar reaction mixture was prepared under the conditions of Example 2-11.
  • Example 2 The reaction mixture of Example 2, Comparative Examples 1 and 2 and 5 g of the mixture of Comparative Example 3 were passed through an SEP-Pak column and eluted with methanol.
  • the eluate was used as a YMC-Pack Pro C 18 column (4.6 ⁇ 250 mm, 5 ⁇ m), and the mobile phase eluted acetonitrile and water in the ratio as shown in Table 3 (Waters 486 Tunable Absorbance Detector).
  • the content of ginsenosides Rb 1 and Rg 3 was measured (standard of Rg 3 : SML0184 of Sigma-Aldrich, standard of Rb 1 : Sigma-Aldrich G0777), and analyzed three times for each sample, and the result of mean ⁇ standard deviation. Was obtained and the results are shown in Table 4.
  • the ginsenoside Rg 3 content was increased in the reaction mixture of Example 2 than the reaction mixture of Comparative Examples 1 and 2 or the mixture of Comparative Example 3, and the content of ginsenoside Rb 1 was largely opposite. It was confirmed that the reduction.
  • CPAE cells calf pulmonary artery endothelial cells
  • FBS fetal bovine serum
  • penicillin-streptomycin 100 units / ml
  • Example 2-1 2.10 ⁇ 0.07 Example 2-2 2.21 ⁇ 0.06 Example 2-3 2.21 ⁇ 0.07 Example 2-4 2.41 ⁇ 0.05 Example 2-5 2.51 ⁇ 0.06 Example 2-6 2.38 ⁇ 0.04 Example 2-7 2.28 ⁇ 0.05 Example 2-8 2.16 ⁇ 0.03 Example 2-9 2.21 ⁇ 0.02 Example 2-10 2.25 ⁇ 0.03 Example 2-11 2.46 ⁇ 0.03 Example 2-12 2.33 ⁇ 0.06 Example 2-13 2.22 ⁇ 0.05 Example 2-14 2.33 ⁇ 0.04 Example 2-15 2.64 ⁇ 0.03 Example 2-16 2.35 ⁇ 0.03 Example 2-17 2.46 ⁇ 0.05 Example 2-18 2.33 ⁇ 0.04 Comparative Example 1-1 1.32 ⁇ 0.04 Comparative Example 1-2 1.43 ⁇ 0.05 Comparative Example 1-3 1.32 ⁇ 0.06 Comparative Example 1-4 1.44 ⁇ 0.07 Comparative Example 1-5 1.35 ⁇ 0.08 Comparative Example 1-6 1.33 ⁇ 0.05 Comparative Example 1-7 1.42 ⁇ 0.06 Comparative Example 1-8 1.36
  • the persimmon vinegar reaction mixture of the red ginseng extract of Example 2 of the present invention was expected to increase the NO production ability due to the increased content of ginsenoside Rg 3 and Arg-Fru and their synergistic effect.
  • distilled water was used instead of the mixture solution.
  • the blank sample (sample blank: HCl was used to stop the reaction first, and then the enzyme was measured for absorbance. The absorbance of the sample was subtracted from the absorbance of the sample. Cycle) 1N hydrochloric acid was added first, followed by addition of crude enzyme solution of angiotensin converting enzyme, 1.5 ml of ethyl acetate was added thereto, followed by stirring for 15 seconds, followed by centrifugation at 2,000 rpm for 20 minutes. Was taken, and completely dried at 100 ° C. for 40 minutes, and then dissolved in 1 ml of distilled water, and the absorbance was measured at 228 nm.
  • Inhibitory effect of the angiotensin converting enzyme according to the measured absorbance was calculated according to the following scheme and shown in Table 8.
  • the reaction value was shown as the fold value when the mixture of the unheated red ginseng extract of Comparative Example 3 and persimmon vinegar was set to 1.00.
  • control group control: buffer instead of sample
  • Example 2-8 2.83 ⁇ 0.06 Example 2-9 3.44 ⁇ 0.04 Example 2-10 3.57 ⁇ 0.03 Example 2-11 3.64 ⁇ 0.02 Example 2-12 3.33 ⁇ 0.05 Example 2-13 2.44 ⁇ 0.04 Example 2-14 2.52 ⁇ 0.03 Example 2-15 2.63 ⁇ 0.02 Example 2-16 2.34 ⁇ 0.05 Example 2-17 2.45 ⁇ 0.04 Example 2-18 2.56 ⁇ 0.03 Comparative Example 1-1 1.34 ⁇ 0.05 Comparative Example 1-2 1.65 ⁇ 0.06 Comparative Example 1-3 1.53 ⁇ 0.05 Comparative Example 1-4 1.44 ⁇ 0.04 Comparative Example 1-5 1.55 ⁇ 0.06 Comparative Example 1-6 1.33 ⁇ 0.05 Comparative Example 1-7 1.
  • Example 2 significantly increased the activity of angiotensin converting enzyme than the reaction mixtures of Comparative Examples 1 and 2 or the mixture of Comparative Example 3.
  • the present study was conducted to investigate the toxicity of the red ginseng extract mixture of the present invention to the animal body acutely (within 24 hours) when ingested in a short period of time and to determine the lethality.
  • PEG-400 / tween-80 / ethanol (8/1/1, v / v / v) was administered only, and the experimental group prepared persimmon vinegar reaction mixture of red ginseng extract of Example 2-11 of the present invention.
  • Persimmon vinegar reaction mixture of the red ginseng extract of Example 2-11 of the present invention was added to the cooking seasoning by 1% by weight to prepare a cooking seasoning for health promotion.
  • the persimmon vinegar reaction mixture of the red ginseng extract of Example 2-11 of the present invention was added to the flour at 0.1% by weight, and bread, cake, cookies, crackers and noodles were prepared using the mixture to prepare health promoting foods.
  • the persimmon vinegar reaction mixture of the red ginseng extract of Example 2-11 of the present invention was added to the soup and the broth in 0.1 wt% to prepare a soup and broth for health promotion.
  • Persimmon vinegar reaction mixture of red ginseng extract of Example 2-11 of the present invention was added to the milk at 0.1% by weight, and various dairy products such as butter and ice cream were prepared using the milk.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/KR2013/001921 2012-03-09 2013-03-11 Composition contenant un mélange réactionnel d'extrait de ginseng rouge et de vinaigre de kaki pour prévenir ou traiter les maladies vasculaires Ceased WO2013133677A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120024212A KR101222845B1 (ko) 2012-03-09 2012-03-09 홍삼 추출물의 감식초 반응 혼합물을 함유한 혈관 질환의 예방 또는 치료용 조성물
KR10-2012-0024212 2012-03-09

Publications (1)

Publication Number Publication Date
WO2013133677A1 true WO2013133677A1 (fr) 2013-09-12

Family

ID=47841974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/001921 Ceased WO2013133677A1 (fr) 2012-03-09 2013-03-11 Composition contenant un mélange réactionnel d'extrait de ginseng rouge et de vinaigre de kaki pour prévenir ou traiter les maladies vasculaires

Country Status (2)

Country Link
KR (1) KR101222845B1 (fr)
WO (1) WO2013133677A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101420270B1 (ko) * 2013-09-26 2014-07-17 주식회사 천지양 홍삼 추출물의 감식초 반응 혼합물을 함유한 전립선 비대증의 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040072153A (ko) * 2003-02-10 2004-08-18 주식회사 바이오사포젠 진세노사이드 Rg3 및 Rh2를 함유함을 특징으로 하는 항고혈압 조성물
KR20050109269A (ko) * 2002-06-26 2005-11-17 주식회사 유유 식초를 이용한 인삼 제제 및 이의 제조방법
KR20110007473A (ko) * 2009-07-16 2011-01-24 씨제이제일제당 (주) 진세노사이드 강화 분획물을 포함하는 혈압 강하용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050109269A (ko) * 2002-06-26 2005-11-17 주식회사 유유 식초를 이용한 인삼 제제 및 이의 제조방법
KR20040072153A (ko) * 2003-02-10 2004-08-18 주식회사 바이오사포젠 진세노사이드 Rg3 및 Rh2를 함유함을 특징으로 하는 항고혈압 조성물
KR20110007473A (ko) * 2009-07-16 2011-01-24 씨제이제일제당 (주) 진세노사이드 강화 분획물을 포함하는 혈압 강하용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOI, D.-J. ET AL.: "Clinical Effects of Korean Ginseng, Korean Red Ginseng, Chinese Ginseng, and American Ginseng on Blood Pressure in Mild Hypertensive Subjects", KOREAN JOURNAL OF ORIENTAL MEDICINE, vol. 27, no. 4, 2006, pages 198 - 208, XP053016341 *

Also Published As

Publication number Publication date
KR101222845B1 (ko) 2013-01-25

Similar Documents

Publication Publication Date Title
RU2294208C2 (ru) Применение экстракта обработанного женьшеня и выделенных из него сапонинов
US10172900B2 (en) Composition with improved bioavailabilty of saponin and method for improving the bioavailability of saponin
KR102064651B1 (ko) 여주 추출물, 구절초 추출물 및 작약 추출물을 유효 성분으로 포함하는, 당뇨 예방 또는 개선용 조성물
KR101307501B1 (ko) 민들레 열수추출물을 유효성분으로 함유하는 면역질환의예방 또는 치료용 조성물
US7371416B2 (en) Method for preparing processed ginseng to obtain increased amount of ginsenoside RG5
US20190076496A1 (en) Polysaccharide digestion inhibitor
KR101336094B1 (ko) 피부 개선용 건강기능식품 조성물 및 그 제조방법
KR20150031373A (ko) 비타민나무 잎 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학 조성물 및 식품 조성물
EP3025721B1 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'asthme comprenant un extrait de pistacia weinmannifolia j. poiss. ex franch ou une fraction de celui-ci
KR20050014615A (ko) 오미자 추출물을 유효성분으로 함유하는 관절염 예방 및치료용 조성물
WO2013133677A1 (fr) Composition contenant un mélange réactionnel d'extrait de ginseng rouge et de vinaigre de kaki pour prévenir ou traiter les maladies vasculaires
KR20040080640A (ko) 항통풍활성을 갖는 개다래 추출물을 함유하는 약학조성물
KR102014922B1 (ko) 감초 유래 글라블리딘을 유효성분으로 하는 소화기능 개선용 조성물
KR101420270B1 (ko) 홍삼 추출물의 감식초 반응 혼합물을 함유한 전립선 비대증의 예방 또는 치료용 조성물
US20060210659A1 (en) Anti-obesity agent
KR101910099B1 (ko) 미성숙 감으로부터 가압 열수 방법으로 추출한 추출물 유효성분으로 포함하는 지질대사 개선 또는 항비만용 조성물
KR20090074337A (ko) 민들레 추출물을 함유하는 고혈압의 예방 및 치료용 조성물
KR20220075860A (ko) 해마 추출물을 유효성분으로 함유하는 전립선암의 예방, 개선, 또는 치료용 조성물
KR100456417B1 (ko) 약효가 증가된 특수가공처리 인삼 추출물을 함유하는뇌졸증의 예방 및 치료를 위한 조성물
KR102441302B1 (ko) 디아세틸 토릴린을 유효성분으로 포함하는 항암용 조성물
KR20200021739A (ko) 분꽃나무 추출물을 포함하는 호흡기 질환 예방, 개선 또는 치료용 조성물
JP2002212085A (ja) 尿酸値低下剤
KR100478150B1 (ko) 생약 복합제 추출물을 유효성분으로 함유하는 당뇨병 예방용 건강보조식품
KR20250081042A (ko) 지방간 유래 간염예방 및 치료용 조성물
KR20250031426A (ko) 골담초근 추출물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13758223

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13758223

Country of ref document: EP

Kind code of ref document: A1